A Study of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Evaluated as a Fixed Dose Combination Regimen in Participants Switching From an Integrase Inhibitor Who Have Experienced Rapid Weight Gain

AIDS Healthcare Foundation-Research Center, New York

Mount Sinai Hospital-New York, New York

Montefiore Medical Center, The Bronx

University of Pennsylvania, Philadelphia

Philadelphia Fight, Philadelphia

Kaiser Permanente, Rockville

Infectious Disease Associates of Central Virginia, Lynchburg

Palmetto Health - USC, Columbia

Atlanta ID Group, Atlanta

Medical College of Georgia, Augusta

The Corporation of Mercer University, Macon

Chatham County Health Department, Savannah

University of Miami, Miami

Triple O Research Institute, West Palm Beach

Midway Immunology and Research Center, Ft. Pierce

University of Alabama at Birmingham, Birmingham

University of Mississippi Medical Center, Jackson

Be Well Medical Center, PC, Berkley

Henry Ford Health System, Detroit

Vivent Health, Milwaukee

The Ruth M. Rothstein CORE Center, Chicago

Washington University School Of Medicine, St Louis

University of Nebraska, Omaha

Care South Clinic, Baton Rouge

AIDS Arms Incorporated Trinity Health and Wellness Center, Dallas

North Texas Infectious Diseases Consultants, Dallas

DCOL Center for Clinical Research, Longview

Texas Centers for Infectious Disease Associates, Fort Worth

Therapeutic Concepts - Donald R Watkins Foundation, Houston

AIDS Health Foundation-Westside HCC, Beverly Hills

Long Beach Education & Research Consultants, Long Beach

The Office of Franco Felizarta, MD, Bakersfield

Community Research Initiative, Boston

Saint Michaels Medical Center - Infectious Disease, Newark